BiotechTube

BDB001

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Tumor, Solid

Conditions

Tumor, Solid

Trial Timeline

Aug 30, 2021 → May 1, 2023

NCT ID
NCT04819373

About BDB001

BDB001 is a phase 2 stage product being developed by Eikon Therapeutics for Tumor, Solid. The current trial status is completed. This product is registered under clinical trial identifier NCT04819373. Target conditions include Tumor, Solid.

What happened to similar drugs?

20 of 20 similar drugs in Tumor, Solid were approved

Approved (20) Terminated (3) Active (0)
✅PexidartinibDaiichi SankyoApproved
✅KRN23Kyowa KirinApproved
✅DurvalumabAstraZenecaApproved
✅aprepitant + Dexamethasone and Ondansetron during CE-treatmentMerckApproved
✅Everolimus (RAD001)NovartisApproved
✅Chromogranin ANovartisApproved
✅Pasireotide + DiazoxideNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04819373Phase 2Completed

Competing Products

20 competing products in Tumor, Solid

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
FruquintinibHUTCHMEDPhase 1
23
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
CixutumumabEli LillyPhase 1
29
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
27